Honor A Blackwood1, Charlie C Hall2,3, Trude R Balstad4,5, Tora S Solheim4,5, Marie Fallon3, Erna Haraldsdottir2,6,7, Barry J Laird2,3. 1. St Columba's Hospice, Centre for Education and Research, Edinburgh, UK. hblackwood@stcolumbashospice.org.uk. 2. St Columba's Hospice, Centre for Education and Research, Edinburgh, UK. 3. Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. 4. Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 5. Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology, Trondheim, Norway. 6. Queen Margaret University, Edinburgh, UK. 7. School of Health Sciences, University of Iceland, Reykjavík, Iceland.
Abstract
PURPOSE: Recent guidelines by the European Society for Clinical Nutrition and Metabolism (ESPEN) have advocated increased attention to nutritional support in all patients with cancer; however, little is known about the optimal type of nutritional intervention. The aim of this review was to assess the current evidence for nutrition support in patients with incurable cancer. METHODS: This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Embase, MEDLINE and CINAHL were searched from 1990 to 2018. Evidence was appraised using a modified risk of bias table, based on guidance from the Cochrane Handbook for Systematic Reviews of Interventions. RESULTS: Sixty studies were assessed of which twelve met the eligibility criteria. Eleven studies examined body composition, with six studies reporting improvements in weight. Six studies examined nutritional status with three studies reporting an improvement. Nine studies examined nutritional intake with six showing improvements including significant improvements in dietary and protein intake. Ten studies examined quality of life, with six studies reporting improvements following intervention. The most common nutritional interventions examined were nutrition counselling and dietary supplementation. CONCLUSIONS: There is moderate quality evidence to support the need for increased attention to nutrition support in patients with incurable cancer; however, despite some statistically significant results being reported, the clinical effects of them were small. Key questions remain as to the optimal timing for these interventions to be implemented (e.g. cachexia stage, illness stage and timing with anticancer therapy) and the most appropriate endpoint measures.
PURPOSE: Recent guidelines by the European Society for Clinical Nutrition and Metabolism (ESPEN) have advocated increased attention to nutritional support in all patients with cancer; however, little is known about the optimal type of nutritional intervention. The aim of this review was to assess the current evidence for nutrition support in patients with incurable cancer. METHODS: This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Embase, MEDLINE and CINAHL were searched from 1990 to 2018. Evidence was appraised using a modified risk of bias table, based on guidance from the Cochrane Handbook for Systematic Reviews of Interventions. RESULTS: Sixty studies were assessed of which twelve met the eligibility criteria. Eleven studies examined body composition, with six studies reporting improvements in weight. Six studies examined nutritional status with three studies reporting an improvement. Nine studies examined nutritional intake with six showing improvements including significant improvements in dietary and protein intake. Ten studies examined quality of life, with six studies reporting improvements following intervention. The most common nutritional interventions examined were nutrition counselling and dietary supplementation. CONCLUSIONS: There is moderate quality evidence to support the need for increased attention to nutrition support in patients with incurable cancer; however, despite some statistically significant results being reported, the clinical effects of them were small. Key questions remain as to the optimal timing for these interventions to be implemented (e.g. cachexia stage, illness stage and timing with anticancer therapy) and the most appropriate endpoint measures.
Authors: Jane A Read; Philip J Beale; Dianne H Volker; Narelle Smith; Annabel Childs; Stephen J Clarke Journal: Support Care Cancer Date: 2006-10-05 Impact factor: 3.603
Authors: Kenneth Fearon; Florian Strasser; Stefan D Anker; Ingvar Bosaeus; Eduardo Bruera; Robin L Fainsinger; Aminah Jatoi; Charles Loprinzi; Neil MacDonald; Giovanni Mantovani; Mellar Davis; Maurizio Muscaritoli; Faith Ottery; Lukas Radbruch; Paula Ravasco; Declan Walsh; Andrew Wilcock; Stein Kaasa; Vickie E Baracos Journal: Lancet Oncol Date: 2011-02-04 Impact factor: 41.316
Authors: Tora S Solheim; Barry J A Laird; Trude Rakel Balstad; Guro B Stene; Asta Bye; Neil Johns; Caroline H Pettersen; Marie Fallon; Peter Fayers; Kenneth Fearon; Stein Kaasa Journal: J Cachexia Sarcopenia Muscle Date: 2017-06-14 Impact factor: 12.910
Authors: P J Ross; S Ashley; A Norton; K Priest; J S Waters; T Eisen; I E Smith; M E R O'Brien Journal: Br J Cancer Date: 2004-05-17 Impact factor: 7.640
Authors: Jocelyn L Tan-Shalaby; Jennifer Carrick; Krystal Edinger; Dana Genovese; Andrew D Liman; Vida A Passero; Rashmikant B Shah Journal: Nutr Metab (Lond) Date: 2016-08-12 Impact factor: 4.169
Authors: Stefano Rotolo; Andrea Di Giorgio; Marco Cintoni; Emanuele Rinninella; Marta Palombaro; Gabriele Pulcini; Carlo Alberto Schena; Vito Chiantera; Giuseppe Vizzielli; Antonio Gasbarrini; Fabio Pacelli; Maria Cristina Mele Journal: Pleura Peritoneum Date: 2022-03-01
Authors: Sarah Alonzi; Michael Hoerger; Laura M Perry; Lydia D Chow; Charlotte Manogue; Patrick Cotogno; Emma M Ernst; Elisa M Ledet; Oliver Sartor Journal: Support Care Cancer Date: 2021-02-10 Impact factor: 3.359
Authors: Carla M Prado; Alessandro Laviano; Chelsia Gillis; Anthony D Sung; Maureen Gardner; Suayib Yalcin; Suzanne Dixon; Shila M Newman; Michael D Bastasch; Abby C Sauer; Refaat Hegazi; Martin R Chasen Journal: Support Care Cancer Date: 2021-11-23 Impact factor: 3.359